Trial Profile
Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to systemic sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2014
Price :
$35
*
At a glance
- Drugs ORM 12741 (Primary)
- Indications Raynaud's disease
- Focus Therapeutic Use
- Sponsors Orion Pharma
- 09 Apr 2014 Integrated data from the EudraCT record.
- 09 Apr 2014 New trial record
- 01 Dec 2011 Primary endpoint 'Blood-flow' has not been met.